Abstract
One of the possible sites of action of the analgesic effect of morphine is the Nucleus Raphe Magnus, as morphine injected into this structure induces analgesia in transient pain models. In order to test if morphine in the Nucleus Raphe Magnus is also analgesic in a tonic pain model, 5 μg of morphine or saline (control) were microinjected into the Nucleus Raphe Magnus of the rat. Analgesic effects were assessed following nociceptive stimulation using transient heating of the tail (phasic pain) and subcutaneous orofacial injection of 1.5 % formalin (tonic pain). While morphine was strongly analgesic for the tail-flick response (p < 0.0001 compared to control), analgesia on the response to formalin was also observed for both early (p = 0.007) and late responses (p = 0.02). However, the response to formalin was not completely blunted. These results suggest that the Nucleus Raphe Magnus is not the exclusive site of action of morphineinduced analgesia in clinical conditions.
Keywords: Opioid, analgesia, trigeminal, tail-flick test, formalin test
Current Drug Delivery
Title: Analgesia Induced by Morphine Microinjected into the Nucleus Raphe Magnus: Effects on Tonic Pain
Volume: 4 Issue: 3
Author(s): Christian Duale, Fernando Sierralta and Radhouane Dallel
Affiliation:
Keywords: Opioid, analgesia, trigeminal, tail-flick test, formalin test
Abstract: One of the possible sites of action of the analgesic effect of morphine is the Nucleus Raphe Magnus, as morphine injected into this structure induces analgesia in transient pain models. In order to test if morphine in the Nucleus Raphe Magnus is also analgesic in a tonic pain model, 5 μg of morphine or saline (control) were microinjected into the Nucleus Raphe Magnus of the rat. Analgesic effects were assessed following nociceptive stimulation using transient heating of the tail (phasic pain) and subcutaneous orofacial injection of 1.5 % formalin (tonic pain). While morphine was strongly analgesic for the tail-flick response (p < 0.0001 compared to control), analgesia on the response to formalin was also observed for both early (p = 0.007) and late responses (p = 0.02). However, the response to formalin was not completely blunted. These results suggest that the Nucleus Raphe Magnus is not the exclusive site of action of morphineinduced analgesia in clinical conditions.
Export Options
About this article
Cite this article as:
Christian Duale , Fernando Sierralta and Radhouane Dallel , Analgesia Induced by Morphine Microinjected into the Nucleus Raphe Magnus: Effects on Tonic Pain, Current Drug Delivery 2007; 4 (3) . https://dx.doi.org/10.2174/156720107781023884
DOI https://dx.doi.org/10.2174/156720107781023884 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DPPH Scavenging Assay of Novel 1,3-disubstituted-1H-pyrazol-5-ols and their in silico Studies on Some Proteins Involved in Alzheimers Disease Signaling Cascade
Letters in Drug Design & Discovery The In Silico Insights of α-Adrenergic Receptors Over the Last Decade: Methodological Approaches and Structural Features of the 3D Models
Current Topics in Medicinal Chemistry Erratum
CNS & Neurological Disorders - Drug Targets Alzheimer’s Drug Discovery Maze: A Snap View of the Past Decade’s Diverse Pharmacological Targets for the Disorder
Mini-Reviews in Medicinal Chemistry The Impact of Natural Compounds on the Treatment of Neurodegenerative Diseases
Current Organic Chemistry NOS: Molecular Mechanisms, Clinical Aspects, Therapeutic and Monitoring Approaches
Current Drug Targets - Inflammation & Allergy Preconditioning by Oxygen-Glucose Deprivation Preserves Cell Proliferation and Reduces Cytotoxicity in Primary Astrocyte Cultures
CNS & Neurological Disorders - Drug Targets Microglia and Inflammation in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution?
Current Pharmaceutical Design Editorial [The Trifluoromethyl Group in Organic Synthesis: Recent Developments (Guest Editor: Simon E. Lopez)]
Current Organic Synthesis Obstructive Sleep Apnea and Cardiovascular Disease - A New Target for Treatment
Current Pharmaceutical Design Jingshu Keli and its Components Notoginsenoside R1 and Ginsenoside Rb1 Alleviate the Symptoms of Cervical Myelopathy through Kir3.1 Mediated Mechanisms
CNS & Neurological Disorders - Drug Targets Targeting SphK1 as a New Strategy against Cancer
Current Drug Targets An Overall Picture of Chemokine Receptors: Basic Research and Drug Development
Current Pharmaceutical Design The Renin Angiotensin System and Bipolar Disorder: A Systematic Review
Protein & Peptide Letters Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Oxidative Stress and Altered Mitochondrial Function in Neurodegenerative Diseases: Lessons From Mouse Models
CNS & Neurological Disorders - Drug Targets Target Prediction of Small Molecules with Information of Key Molecular Interactions
Current Topics in Medicinal Chemistry Pregnancy and Sleep Apnea
Current Respiratory Medicine Reviews Strategies for Stalling Malignancy: Targeting Cancers Addiction to Hsp90
Current Topics in Medicinal Chemistry